1

5April2017 MEDIARELEASEAdvancedtherapymanufacturingandautomationexperts,Scinogy,joinCTMCRCtoacceleratedevelopmentofnextgencelltherapymanufacturingAdvancedtherapymanufacturingtechnologyandscale-upspecialists,ScinogyhavejoinedtheCRCforCellTherapyManufacturing(CTMCRC).TheadditionofScinogy’sexperienceinmanufacturingsystemsforcelltherapy,complementsCTMCRC’sexpertiseinsurfacefunctionalisationandnewmaterialstechnologies.Thispowerfulcombinationofcapabilitieswillbetteraddresscurrentmanufacturingchallenges,suchasscalabilityandcost.“Withtheclinicalprogressandrapidgrowthinadvancedtherapies,thetimeisrighttoaddressthechallengesfacingcommercialsuccess.Asprocessesforthemanufactureoftheseproductsarelockedinataveryearlystageofdevelopment,earlyadoptionoftechnologiesthatarescalable,reproducible,transferableandcommerciallyviableiscriticallyimportant.IntegrationofCTMCRC’ssurfaceoptimisationwithScinogy’sautomatedclosedsystemswillprovideapowerfultooltowardsmorecosteffectiveandscalableapproachestomanufacturing.”DrSherryKothari,CEOofCTMCRC,said.Advancedtherapycompaniesmusthaveconfidenceintheirclinicaldataandproducts.Processintegrityensuresthatthesameprocesshasbeenperformedforeverypatient,everybatch,everysite,everytime.“ThecombinationofScinogy’sexpertiseinthedevelopmentofclosed,automatedmanufacturingsystemsandsingle-usekitsinadditiontoCTMCRC’ssurfacefunctionalisationcapabilities,providesanidealopportunitytocreatenextgenmanufacturingprocessesthatarereproducible,scalableandcosteffectivefromtheoutset,”MrDavidJames,CEOofScinogy,said.ThecollaborationbetweenthetwocompanieswillbeginwithafocusonTcells,initiallytailoredtosimplifyChimericAntigenReceptorTcell(CAR-T)manufacture,currentlyofinterestinthefieldforthedevelopmentofimmunotherapiesforthetreatmentofcancer.AsignificantadvantageoftheScinogy/CTMCRCcollaborationisthatbothcompaniesaredevelopingplatformtechnologies,whichcanbeadaptedtoprovideflexible,configurablesystems,tailoredtosuitdifferentprocessesforarangeofcelltypes.

2

ThisisanexcitingtimefortheindustryandtheCTMCRC/Scinogypartnership,anddovetailswithCTMCRC’snewtranslationalfacility,TekCyte,fortheseamlessandefficientscaleupofmanufacturingprocessesfromthelabtocommercialscale.ThisalsoprovidesanopportunitytoestablishauniquecelltherapycapabilityinAustralia.

-Ends-AboutScinogyScinogyspecialisesinthedevelopmentofautomationandsingle-use-kitsforthemanufactureofadvancedtherapies.Scinogy’shighperformanceteamcombinesgreatscience,therighttechnologyandcommercialexperiencetohelpmakeyourclinicalresultsacommercialreality.AbouttheCRCforCellTherapyManufacturingCelltherapy,theuseoflivingcellstorepair,replaceorregeneratediseasedordamagedtissueistransforminghealthcareparadigmsglobally.Throughinterventionwithnovelcoatingsandsmartmaterialstechnologies,theCRCforCellTherapyManufacturingwillintroduceefficienciesincelltherapymanufacturingprocesses,suchascellisolation,expansionanddelivery.This,inturn,willdecreasecostsassociatedwithmanufacturingandfacilitatetherapidtranslationofcelltherapiesintoclinicalpractice.TheCRChasavisiontoincreasetheaccessibility,affordabilityandefficacyofcelltherapiesforpreviouslyincurable,ordifficulttotreatconditionssuchastype1diabetes,chronicwoundsandimmune-mediateddiseases.

Forfurtherinformationandmediaenquiriescontact:

NatalieWatkinsMarketing&CommunicationsManager

CRCforCellTherapyManufacturing+61883023917

natalie.watkins@ctmcrc.com